Towards in vivo application of RNA interference – new toys, old problems
Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Arthritis Res Ther 2004, 6:78-85 doi:10.1186/ar1168Published: 10 March 2004
RNA interference (RNAi) is the sequence-specific degradation of mRNA by short double-stranded RNA molecules. The technology, introduced only 5 years ago, has stimulated many fantasies regarding the future of functional gene analysis and gene therapy. Given its ease of application, its high efficiency and remarkable specificity, RNAi holds great promise for broad in vitro and in vivo application in all areas of biomedicine. Despite its potential, the major obstacle to the use of RNAi (as for all previous gene silencing approaches) is the need for efficient and sustained delivery of small interfering RNA into primary mammalian cells, and specific targeting of particular cell types in vivo.